[1]马晓颖.普拉克索联合多巴丝肼治疗帕金森病的效果及对脑血流量的影响[J].医学信息,2022,35(07):134-136.[doi:10.3969/j.issn.1006-1959.2022.07.034]
　MA Xiao-ying.Effect of Pramipexole Combined with Dobutazide in the Treatment of Parkinson’s Disease and its Effect on Cerebral Blood Flow[J].Medical Information,2022,35(07):134-136.[doi:10.3969/j.issn.1006-1959.2022.07.034]
点击复制

普拉克索联合多巴丝肼治疗帕金森病的效果及对脑血流量的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年07期
页码:
134-136
栏目:
论著
出版日期:
2022-04-01

文章信息/Info

Title:
Effect of Pramipexole Combined with Dobutazide in the Treatment of Parkinson’s Disease and its Effect on Cerebral Blood Flow
文章编号:
1006-1959（2022）07-0134-03
作者:
马晓颖
（大连市第四人民医院内四科，辽宁 大连 116000）
Author(s):
MA Xiao-ying
(The Forth Department of Internal Medicine,Dalian the Fourth People’s Hospital,Dalian 116000,Liaoning,China)
关键词:
普拉克索; 多巴丝肼; 帕金森病; 脑血流量
Keywords:
Pramipexole; Dobutamine; Parkinson’s disease; Cerebral blood flow
分类号:
R742.5
DOI:
10.3969/j.issn.1006-1959.2022.07.034
文献标志码:
A
摘要:
目的 观察普拉克索联合多巴丝肼治疗帕金森病的临床疗效，并研究其对脑血流量的影响。方法 选取2020年4月-2021年4月在我院诊治的92例帕金森病患者为研究对象，采用随机数字表法分为对照组和观察组，各46例。对照组采用多巴丝肼治疗，观察组在对照组基础上联合普拉克索治疗，比较两组治疗总有效率、左基底和右基底节区脑血流、神经症状评分、冻结步态（FOG-Q）评分以及不良反应发生情况。结果 观察组治疗总有效率为93.48%，高于对照组的80.43%，差异有统计学意义（P＜0.05）；两组左基底、右基底节区脑血流均大于治疗前，且观察组大于对照组，差异有统计学意义（P＜0.05）；观察组口干、出汗、尿频尿急、便秘、流涎评分均低于对照组，差异有统计学意义（P＜0.05）；两组FOG-Q评分均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 普拉克索联合多巴丝肼治疗帕金森病效果显著，可改善患者脑血流量，减轻其神经症状，改善步态障碍，不良反应少，安全性良好。
Abstract:
Objective To observe the clinical efficacy of pramipexole combined with dobutazide in the treatment of Parkinson’s disease and to study its effect on cerebral blood flow.Methods A total of 92 patients with Parkinson ’ s disease who were treated in our hospital from April 2020 to April 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 46 cases in each group. The control group was treated with dobutazide, and the observation group was treated with pramipexole on the basis of the control group. The total effective rate, cerebral blood flow in left and right basal ganglia, neurological symptom score, frozen gait (FOG-Q) score and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 93.48%, which was higher than 80.43% of the control group, and the difference was statistically significant (P<0.05). The cerebral blood flow in the left basal ganglia and right basal ganglia of the two groups was greater than that before treatment, and the observation group was greater than the control group, the difference was statistically significant (P<0.05). The scores of dry mouth, sweating, frequent urination, constipation and salivation in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). The FOG-Q scores of the two groups were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Pramipexole combined with dobutazide is effective in the treatment of Parkinson’s disease, which can improve cerebral blood flow, relieve neurological symptoms, improve gait disorder, with less adverse reactions and good safety.

参考文献/References:

[1]孙绍武.普拉克索联合左旋多巴对晚期帕金森病患者临床症状及负性情绪的影响[J].中国实用神经疾病杂志,2017,20(4):118-120.[2]中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会．中国帕金森病的诊断标准( 2016 版) [J].中华神经科杂志,2016,49(4):268-271．[3]吕鸿利.氯氮平片联合多巴丝肼片治疗帕金森病伴发精神障碍临床研究观察[J].医药论坛杂志,2018,39(9):162-163.[4]周婷,李青叶.普拉克索与溴隐亭治疗帕金森病患者疗效及安全性对照研究[J].中国实用神经疾病杂志,2016,19(5):109-110.[5]孙慧丽.普拉克索联合美多芭治疗帕金森病效果观察[J].山东医药,2017,57(42):83-85．[6]郑丽芬,林萍,张旭,等罗西汀片联合普拉克索片治疗帕金森病伴抑郁的临床研究[J].中国临床药理学杂志,2018,34(15):1819-1821．[7]张正祥,杜丽,刘新亚,等.美多芭联合盐酸普拉克索治疗帕金森病非运动症状的有效性及安全性分析[J].神经损伤与功能重建,2017,12(6):558-560.[8]Park HW,Park CG,Park M,et al.Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model[J].Entific Reports,2020,10(1):9572.[9]任明慧,吴苏宁.多巴丝肼结合普拉克索治疗帕金森疗效及不良反应临床观察[J].中国继续医学教育,2018,10(9):110[10]石莺,彭汉芬.多巴丝肼联合普拉克索治疗帕金森症的临床疗效[J].现代诊断与治疗,2018,29(6):864-866. [11]赖琼,赵晓玲,李立,等.普拉克索、多巴丝肼初始单独或联合治疗对帕金森病非运动症状患者认知功能和血液学指标的影响[J].实用医院临床杂志,2020,17(5):148-152.[12]郝世胜,李娟.普拉克索联合多巴丝肼片治疗帕金森病的临床效果评价[J].中国继续医学教育,2017,9(34):87-89. [13]郑宋华.多巴丝肼联合普拉克索治疗帕金森的临床疗效及安全性分析[J].现代医院,2017,17(9):1333-1335. [14]张兰.盐酸普拉克索联合多巴丝肼对帕金森氏病的临床效果[J].包头医学院学报,2017,33(9):74-75.[15]Guin D,Mishra MK,Talwar P,et al.A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson’s disease[J].BMC Med Genomics,2017,10(1):56.[16]周永,陈蓝,戴杰,等.普拉克索联合左旋多巴治疗帕金森病的临床疗效及安全性[J].药物评价研究,2018,41(12):136-139.[17]陈丹.美多芭联合普拉克索对帕金森病的临床疗效及安全性研究[J].河北医学,2018,24(11):1903-1906.[18]纪新博,顾申红,容琼文,等.盐酸普拉克索配合神经节苷脂对帕金森患者血清炎症因子及运动功能的影响[J].现代中西医结合杂志,2016,25(24):2693-2695．[19]张诚,钟平,汪国胜,等.普拉克索联合苯海索对帕金森患者认知功能及生活质量的影响[J].河北医药,2020,42(2):77-80,84.[20]邢晓莲,李伟荣.普拉克索联合多巴丝肼治疗帕金森病的疗效及对血清同型半胱氨酸胰岛素样生长因子 1 水平的影响[J].山西医药杂志,2019,48(20):59-61.

相似文献/References:

[1]李 鹏,李爱歆.美多巴联合普拉克索治疗帕金森病的有效性及安全性[J].医学信息,2020,33(09):146.[doi:10.3969/j.issn.1006-1959.2020.09.048]
　LI Peng,LI Ai-xin.The Efficacy and Safety of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Disease[J].Medical Information,2020,33(07):146.[doi:10.3969/j.issn.1006-1959.2020.09.048]
[2]褚春沐.多巴丝肼联合普拉克索治疗帕金森的疗效及不良反应研究[J].医学信息,2022,35(18):112.[doi:10.3969/j.issn.1006-1959.2022.18.030]
　CHU Chun-mu.Study on Efficacy and Adverse Reactions of Dopazide Combined with Pramipexole in Treatment of Parkinson’s Disease[J].Medical Information,2022,35(07):112.[doi:10.3969/j.issn.1006-1959.2022.18.030]

更新日期/Last Update: 1900-01-01